Drugs / EMIRODATAMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03541369 | Sep 2018 → Feb 2023 | acute myeloid leukemia | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMIRODATAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297881 ↗ |
| Known as | AMG 427 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03541369 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4297881 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT03541369 ↗ |